


NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide.

ETCTN Lymphoma Trials (Open as of 9/10/2026)

Protocol Number	Phase	Protocol Title
10299	I	A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients
10335	I	A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)
10508	I/II	A Phase 1 Study of Nivolumab in Combination with ASTX727 in B-cell Lymphoma (NHL or HL) with an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin lymphoma (HL)
10590	II	A Phase 2 Study of Mosunetuzumab or Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma
10601	I	A Phase 1 Study of Mosunetuzumab with Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
10664	Ib	Phase 1b Study of Combination Tovorafenib and Rituximab Treatment in Relapsed or Refractory Classical Hairy Cell Leukemia and Phase 2 Randomized Study Comparing Tovorafenib and Rituximab with Cladribine and Rituximab for Front-Line Treatment of Classical Hairy Cell Leukemia
10702	II	A Phase II Study of Glofitamab for Relapsed/Refractory Mantle Cell Lymphoma in Patients Previously Treated with CD19-Directed CAR T-Cell Therapy
10717	Ib/II	Phase 1b/2 Trial of Pidnarulex in MYC Aberrant Lymphoma
10727	Ib	Phase 1b study of teclistamab in relapsed/refractory plasmablastic lymphoma
10760	I	A Phase I Study of Glofitamab with Alternating R-CHOP/R-DHAP in Previously Untreated Mantle Cell Lymphoma
10799	II	A Randomized Phase II study of Pembrolizumab with or without Entinostat in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma